keyword
MENU ▼
Read by QxMD icon Read
search

cinv

keyword
https://www.readbyqxmd.com/read/28871358/chemotherapy-induced-nausea-and-vomiting-cinv-and-adherence-to-antiemetic-guidelines-results-of-a-survey-of-oncology-nurses
#1
Rebecca Clark-Snow, Mary Lou Affronti, Cynthia N Rittenberg
PURPOSE: Chemotherapy-induced nausea and vomiting (CINV) can be prevented in most patients with use of guideline-recommended antiemetic regimens. However, studies have suggested that adherence to antiemetic guidelines is suboptimal. Oncology nurses, as part of a multidisciplinary team, can help promote appropriate antiemetic prophylaxis. Therefore, nurses were surveyed to assess antiemetic guideline awareness and practice patterns of antiemetic use, determine adherence to guideline recommendations, and query barriers to adherence...
September 4, 2017: Supportive Care in Cancer: Official Journal of the Multinational Association of Supportive Care in Cancer
https://www.readbyqxmd.com/read/28861627/is-the-addition-of-a-neurokinin-1-receptor-antagonist-beneficial-in-moderately-emetogenic-chemotherapy-a-systematic-review-and-meta-analysis
#2
Karin Jordan, Luisa Blättermann, Axel Hinke, Carsten Müller-Tidow, Franziska Jahn
PURPOSE: This systematic review evaluates the efficacy of neurokinin-1 receptor antagonists (NK1RAs) for the prevention of chemotherapy-induced nausea and vomiting (CINV) in moderately emetogenic chemotherapy (MEC) excluding anthracycline-cyclophosphamide-based regimens. METHODS: A systematic review of MEDLINE (via PubMed and OVID) and Central databases, plus major oncology conferences, identified randomized trials evaluating NK1RAs in combination with a 5-HT3 RA plus a glucocorticoid for management of CINV...
August 31, 2017: Supportive Care in Cancer: Official Journal of the Multinational Association of Supportive Care in Cancer
https://www.readbyqxmd.com/read/28856448/olanzapine-for-prevention-of-chemotherapy-induced-nausea-and-vomiting-in-children-and-adolescents-a-multi-center-feasibility-study
#3
J Flank, T Schechter, P Gibson, D L Johnston, A D Orsey, C Portwine, L Sung, L L Dupuis
CONTEXT: There are no prospective pediatric trials evaluating olanzapine for chemotherapy-induced nausea and vomiting (CINV) prevention. OBJECTIVE: This study evaluated the feasibility of a trial of olanzapine to evaluate the contribution of olanzapine to CINV control in pediatric oncology patients. METHODS: Patients < 18 years receiving CINV prophylaxis with ondansetron/granisetron/palonosetron ± dexamethasone ± aprepitant were eligible to participate in this prospective, single-arm, open-label study...
August 30, 2017: Supportive Care in Cancer: Official Journal of the Multinational Association of Supportive Care in Cancer
https://www.readbyqxmd.com/read/28844591/addition-of-3-day-aprepitant-to-ondansetron-and-dexamethasone-for-prophylaxis-of-chemotherapy-induced-nausea-and-vomiting-among-patients-with-diffuse-large-b-cell-lymphoma-receiving-5-day-cisplatin-based-chemotherapy
#4
Raafat Abdel-Malek, Noha Abbas, Kyrillus S Shohdy, Mohamed Ismail, Radwa Fawzy, Dalal S Salem, Ezzat Safwat
BACKGROUND: Neurokinin-1 receptor antagonists, such as aprepitant are currently emerging as powerful prophylactic agents for chemotherapy-induced nausea and vomiting (CINV). Therefore, it is important to adjust the anti-emetic regimens based on personal risk factors of the patient, duration of the chemotherapy regimen and cost-effectiveness. PURPOSE: To determine the efficacy of the 3-day aprepitant along with ondansetron and dexamethasone in controlling CINV in patients with large B cell lymphoma receiving multiday-cisplatin regimen chemotherapy...
August 22, 2017: Journal of the Egyptian National Cancer Institute
https://www.readbyqxmd.com/read/28823027/a-prospective-study-of-palonosetron-for-prevention-of-chemotherapy-induced-nausea-and-vomiting-in-malignant-lymphoma-patients-following-highly-emetogenic-chemotherapy
#5
Tsutomu Takahashi, Takahiro Okada, Fumiyoshi Ikejiri, Shunsuke Ito, Yusuke Okada, Fumimasa Takahashi, Satoshi Kumanomido, Yumi Jo, Koji Adachi, Chie Onishi, Koshi Kawakami, Takaaki Miyake, Masaya Inoue, Ritsuro Suzuki, Junji Suzumiya
BACKGROUND: Chemotherapy-induced nausea and vomiting (CINV) is a troublesome issue in chemotherapy for cancer patients. A second-generation 5HT3 receptor antagonist (5HT3RA), palonosetron, is effective and safe for the prevention of CINV in breast cancer patients treated with cyclophosphamide and anthracycline, but there is little data for malignant lymphoma. We conducted a prospective phase 2 study at a single institution to clarify the efficacy and safety of palonosetron in lymphoma patients...
August 19, 2017: International Journal of Clinical Oncology
https://www.readbyqxmd.com/read/28805667/the-effect-of-a-standardized-ginger-extract-on-chemotherapy-induced-nausea-related-quality-of-life-in-patients-undergoing-moderately-or-highly-emetogenic-chemotherapy-a-double-blind-randomized-placebo-controlled-trial
#6
Wolfgang Marx, Alexandra L McCarthy, Karin Ried, Dan McKavanagh, Luis Vitetta, Avni Sali, Anna Lohning, Elisabeth Isenring
Ginger supplementation could be an effective adjuvant treatment for chemotherapy-induced nausea (CIN). The aim of this clinical trial was to address significant methodological limitations in previous trials. Patients (N = 51) were randomly allocated to receive either 1.2 g of standardised ginger extract or placebo per day, in addition to standard anti-emetic therapy, during the first three cycles of chemotherapy. The primary outcome was CIN-related quality of life (QoL) measured with the Functional Living Index- Emesis (FLIE) questionnaire...
August 12, 2017: Nutrients
https://www.readbyqxmd.com/read/28780725/a-review-of-oral-cannabinoids-and-medical-marijuana-for-the-treatment-of-chemotherapy-induced-nausea-and-vomiting-a-focus-on-pharmacokinetic-variability-and-pharmacodynamics
#7
REVIEW
Melissa E Badowski
PURPOSE: Oral cannabinoids (i.e., dronabinol, nabilone) containing the active component of marijuana, delta(Δ)9-tetrahydrocannabinol (THC), are available for the treatment of chemotherapy-induced nausea and vomiting (CINV) in patients with cancer who have failed to adequately respond to conventional antiemetic therapy. The aim of this article is to provide an overview of the efficacy, pharmacokinetics (PK), pharmacodynamics (PD), and safety of oral cannabinoids for patients with CINV...
August 5, 2017: Cancer Chemotherapy and Pharmacology
https://www.readbyqxmd.com/read/28765126/cost-utility-and-budget-impact-analyses-of-the-use-of-nepa-for-chemotherapy-induced-nausea-and-vomiting-prophylaxis-in-italy
#8
Umberto Restelli, Gabriella Saibene, Patrizia Nardulli, Roberta Di Turi, Erminio Bonizzoni, Francesca Scolari, Tania Perrone, Davide Croce, Luigi Celio
OBJECTIVE: To evaluate the efficiency of resources allocation and sustainability of the use of netupitant+palonosetron (NEPA) for chemotherapy-induced nausea and vomiting (CINV) prophylaxis assuming the Italian National Health Service (NHS) perspective. A published Markov model was adapted to assess the incremental cost-utility ratio of NEPA compared with aprepitant (APR) + palonosetron (PALO), fosaprepitant (fAPR) + PALO, APR + ondansetron (ONDA), fAPR + ONDA in patients receiving a highly emetogenic chemotherapy (HEC) and with APR + PALO and fAPR + PALO in patients receiving a moderately emetogenic chemotherapy (MEC)...
August 1, 2017: BMJ Open
https://www.readbyqxmd.com/read/28735677/genetic-risk-factors-associated-with-antiemetic-efficacy-of-palonosetron-aprepitant-and-dexamethasone-in-japanese-breast-cancer-patients-treated-with-anthracycline-based-chemotherapy
#9
Satoshi Yokoyama, Satoshi Tamaru, Shinya Tamaki, Daisuke Nakanishi, Akiya Mori, Tomokazu Yamakawa, Takaaki Ao, Yasuhiko Sakata, Toshiro Mizuno, Takuya Iwamoto, Kenichi Watanabe, Makoto Simomura, Keiki Kawakami, Naomi Konishi, Shinichi Kageyama, Shoichiro Ohtani, Tomomi Yamada, Susumu Ban, Kazuya Ooi
INTRODUCTION: Breast cancer patients often receive anthracycline-based chemotherapy, and chemotherapy-induced nausea and vomiting (CINV) remains one of the most uncomfortable and distressing adverse reactions. Poor control of CINV reduces the relative dose intensity of chemotherapy agents, which has been associated with poor clinical outcomes and shorter survival. The aim of the present study was to identify genetic risk factors associated with anthracycline-based CINV. PATIENTS AND METHODS: We evaluated CINV attributable to anthracycline-based chemotherapy in Japanese breast cancer patients treated with an antiemetic regimen that included palonosetron, aprepitant, and dexamethasone...
June 29, 2017: Clinical Breast Cancer
https://www.readbyqxmd.com/read/28733700/feasibility-of-olanzapine-multi-acting-receptor-targeted-antipsychotic-agent-for-the-prevention-of-emesis-caused-by-continuous-cisplatin-or-ifosfamide-based-chemotherapy
#10
Seiko Bun, Kan Yonemori, Toru Akagi, Emi Noguchi, Tatsunori Shimoi, Akihiko Shimomura, Mayu Yunokawa, Chikako Shimizu, Yasuhiro Fujiwara, Yoshinori Makino, Yoshikazu Hayashi, Kenji Tamura
Background To determine the feasibility and efficacy of olanzapine, which is approved by the Pharmaceuticals and Medical Devices Agency as multi acting receptor targeted antipsychotic agent of the thienobenzodiazepine class, for prevention of chemotherapy-induced nausea and vomiting (CINV) in patients undergoing continuous five-day chemotherapy. Patients and methods This study was a prospective dose escalation study at a single center (UMIN ID: UMIN000015386). Patients received a combination of adriamycin and ifosfamide (AI) or a combination of bleomycin, etoposide, and cisplatin (BEP)...
July 21, 2017: Investigational New Drugs
https://www.readbyqxmd.com/read/28694084/olanzapine-reduces-chemotherapy-induced-nausea-and-vomiting-compared-with-aprepitant-in-myeloma-patients-receiving-high-dose-melphalan-before-stem-cell-transplantation-a-retrospective-study
#11
Steven Trifilio, Colleen Welles, Kristin Seeger, Shivani Mehta, MaryAnne Fishman, Katherine McGowan, Kathryn Strejcek, Emily Eiten, Carolyn Pirotte, Elizabeth Lucier, Sean DeFrates, Jayesh Mehta
INTRODUCTION: Acute and delayed chemotherapy-induced nausea and vomiting (CINV) occurs in most patients who receive high-dose melphalan and significantly affects patients' quality of life during autologous stem cell transplantation. Faced with unsatisfactory results using an aprepitant-based regimen, an olanzapine-based regimen was initiated, with the hope of improving the incidence of acute and delayed CINV. A retrospective study was conducted to compare the effectiveness of olanzapine- versus aprepitant-based regimens for CINV prevention in adult hematopoietic stem cell recipients who received high-dose melphalan...
June 20, 2017: Clinical Lymphoma, Myeloma & Leukemia
https://www.readbyqxmd.com/read/28691209/efficacy-of-the-oral-neurokinin-1-receptor-antagonist-aprepitant-for-nausea-and-vomiting-induced-by-cisplatin-and-carboplatin-in-japanese-patients-with-gynecological-cancer
#12
Masae Ikeda, Masako Shida, Takeshi Hirasawa, Toshinari Muramatsu, Mikio Mikami
AIM: This study was conducted to evaluate the efficacy and the difference in effects of the oral neurokinin-1(NK-1) receptor antagonist aprepitant for chemotherapy-induced nausea/vomiting (CINV) in Japanese patients with gynecological cancer receiving highly emetogenic (cisplatin) and moderately emetogenic (carboplatin) chemotherapy. METHODS: Aprepitant was added during the second course of chemotherapy in Japanese patients with grade ≥ 2 (Common Terminology Criteria for Adverse Events, version 3...
July 10, 2017: Journal of Obstetrics and Gynaecology Research
https://www.readbyqxmd.com/read/28666335/a-randomized-double-blind-placebo-controlled-multicenter-study-of-a-ginger-extract-in-the-management-of-chemotherapy-induced-nausea-and-vomiting-cinv-in-patients-receiving-high-dose-cisplatin
#13
P Bossi, D Cortinovis, S Fatigoni, M Cossu Rocca, A Fabi, P Seminara, C Ripamonti, S Alfieri, R Granata, C Bergamini, F Agustoni, P Bidoli, F Nolè, M A Pessi, F Macchi, L Michellini, F Montanaro, F Roila
Background: The activity of ginger in the management of chemotherapy-induced nausea and vomiting (CINV) has been suggested, but design inadequacies, heterogeneity of the population, small numbers and poor quality of tested products limit the possibility to offer generalizable results. Patients and methods: We conducted a randomized, double-blind, placebo-controlled, multicenter study in patients planned to receive ≥2 chemotherapy cycles with high dose (>50 mg/m 2 ) cisplatin...
June 28, 2017: Annals of Oncology: Official Journal of the European Society for Medical Oncology
https://www.readbyqxmd.com/read/28658796/comparison-of-antiemetic-effectiveness-of-palonosetron-versus-ondansetron-in-patients-on-cancer-chemotherapy-a-prospective-observational-study-in-south-indians
#14
Abdul Aslam Parathoduvil, Asha Sisupalan, Padanayil Lekshmikutty Rema
INTRODUCTION: Chemotherapy Induced Nausea and Vomiting (CINV) is the most distressing side effect of cancer chemotherapy. It can seriously produce an impact on patient's quality of life. Prevention of CINV is far more effective than treatment of an established CINV. If the patient receives an optimal antiemetic regimen during the initial course of chemotherapy, the likelihood of developing emesis is greatly reduced. Although, all first generation 5HT3 antagonists demonstrate reasonable efficacy in preventing acute CINV, delayed CINV still remains a problem...
May 2017: Journal of Clinical and Diagnostic Research: JCDR
https://www.readbyqxmd.com/read/28657216/additive-effect-of-rikkunshito-an-herbal-medicine-on-chemotherapy-induced-nausea-vomiting-and-anorexia-in-uterine-cervical-or-corpus-cancer-patients-treated-with-cisplatin-and-paclitaxel-results-of-a-randomized-phase-ii-study-jortc-kmp-02
#15
Shunsuke Ohnishi, Hidemichi Watari, Maki Kanno, Yoko Ohba, Satoshi Takeuchi, Tempei Miyaji, Shunsuke Oyamada, Eiji Nomura, Hidenori Kato, Toru Sugiyama, Masahiro Asaka, Noriaki Sakuragi, Takuhiro Yamaguchi, Yasuhito Uezono, Satoru Iwase
OBJECTIVE: Rikkunshito, an herbal medicine, is widely prescribed in Japan for the treatment of anorexia and functional dyspepsia, and has been reported to recover reductions in food intake caused by cisplatin. We investigated whether rikkunshito could improve chemotherapy-induced nausea and vomiting (CINV) and anorexia in patients treated with cisplatin. METHODS: Patients with uterine cervical or corpus cancer who were to receive cisplatin (50 mg/m² day 1) and paclitaxel (135 mg/m² day 0) as first-line chemotherapy were randomly assigned to the rikkunshito group receiving oral administration on days 0-13 with standard antiemetics, or the control group receiving antiemetics only...
September 2017: Journal of Gynecologic Oncology
https://www.readbyqxmd.com/read/28612633/granisetron-in-the-treatment-of-chemotherapy-induced-nausea-and-vomiting-cinv-is-there-still-a-role-after-comparison-with-palonosetron
#16
REVIEW
Sheila A Doggrell
Chemotherapy-induced nausea and vomiting (CINV) has a negative impact on the lives of subjects receiving chemotherapy. In 2009, the second generation 5-HT3-receptor antagonist, palonosetron, which is longer-acting than granisetron, was shown, as part of dual therapy with dexamethasone, to be superior to intravenous granisetron in the delayed phase of CINV. Area covered: In an attempt to maintain plasma levels of granisetron during the delayed phase of CINV, longer-acting preparations of granisetron have been manufactured...
July 2017: Expert Opinion on Pharmacotherapy
https://www.readbyqxmd.com/read/28595433/managing-chemotherapy-induced-nausea-and-vomiting-in-head-and-neck-cancer-patients-receiving-cisplatin-chemotherapy-with-concurrent-radiation
#17
Jordan Stinson, Kelvin Chan, Justin Lee, Ronald Chow, Paul Cheon, Angie Giotis, Mark Pasetka, Bo Angela Wan, Edward Chow, Carlo DeAngelis
BACKGROUND: The purpose was to retrospectively examine the anti-emetic regimens prescribed for prophylaxis of chemotherapy-induced nausea and vomiting (CINV) for head and neck cancer patients receiving moderate- or high-emetogenic chemotherapy (MEC/HEC) along with concurrent radiation treatment at an outpatient ambulatory care center to determine the efficacy of anti-emetics prescribed. METHODS: Consecutive patients with head and neck cancers who initiated cisplatin chemotherapy with concurrent radiation treatment between January 2013 and June 2015 were investigated...
March 21, 2017: Annals of Palliative Medicine
https://www.readbyqxmd.com/read/28581463/the-burden-of-chemotherapy-induced-nausea-and-vomiting-in-children-receiving-hematopoietic-stem-cell-transplantation-conditioning-a-prospective-study
#18
J Flank, J Sparavalo, H Vol, L Hagen, R Stuhler, D Chong, S Courtney, J J Doyle, A Gassas, T Schechter, L L Dupuis
This prospective study describes chemotherapy-induced nausea and vomiting (CINV) in children (4-18 years) receiving their first hematopoietic stem cell transplant. Emetic episodes, nausea severity (assessed using a validated, self-report nausea severity assessment tool) and antiemetic administration were documented from the start of conditioning until 24 h after the last conditioning agent was administered (acute) and for a further 7 days (delayed). Relationships between CINV control and parenteral nutrition (PN) use and acute gut GvHD (aGvHD) were explored...
September 2017: Bone Marrow Transplantation
https://www.readbyqxmd.com/read/28579832/apf530-versus-ondansetron-each-in-a-guideline-recommended-three-drug-regimen-for-the-prevention-of-chemotherapy-induced-nausea-and-vomiting-due-to-anthracycline-plus-cyclophosphamide-based-highly-emetogenic-chemotherapy-regimens-a-post-hoc-subgroup-analysis
#19
Ian D Schnadig, Richy Agajanian, Christopher Dakhil, Nashat Gabrail, Jeffrey Vacirca, Charles Taylor, Sharon Wilks, Eduardo Braun, Michael C Mosier, Robert B Geller, Lee Schwartzberg, Nicholas Vogelzang
BACKGROUND: APF530, a novel extended-release granisetron injection, was superior to ondansetron in a guideline-recommended three-drug regimen in preventing delayed-phase chemotherapy-induced nausea and vomiting (CINV) among patients receiving highly emetogenic chemotherapy (HEC) in the double-blind Phase III Modified Absorption of Granisetron In the prevention of CINV (MAGIC) trial. PATIENTS AND METHODS: This MAGIC post hoc analysis evaluated CINV prevention efficacy and safety of APF530 versus ondansetron, each with fosaprepitant and dexamethasone, in patient subgroup receiving an anthracycline plus cyclophosphamide (AC) regimen...
2017: Cancer Management and Research
https://www.readbyqxmd.com/read/28503222/olanzapine-for-chemotherapy-induced-nausea-and-vomiting-systematic-review-and-meta-analysis
#20
Legese Chelkeba, Kidu Gidey, Ayele Mamo, Berhane Yohannes, Tsehay Matso, Tsegaye Melaku
BACKGROUND: Chemotherapy induced nausea and vomiting (CINV) remains the most distressing event in patients receiving highly emetogenic chemotherapy (HEC) or moderately emetogenic chemotherapy (MEC). OBJECTIVE: Therefore, this meta-analysis was conducted to evaluate the efficacy of olanzapine containing regimen in preventing acute, delayed and overall phases of CINV. METHODS: PubMed, EBSCO, and Cochrane central register of controlled trials electronic databases were searched to identify RCTs that compared the effects of olanzapine with non-olanzapine regimen in preventing CINV...
January 2017: Pharmacy Practice
keyword
keyword
28477
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"